Hiroshige Yoshioka

18PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsChemotherapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 30, 2026
Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L).

|Sep 03, 2026
A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC.

|May 14, 2026
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

|Apr 21, 2026
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

|Dec 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).

Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

Pageof 3

Frequent Collaborators

5 joint publications

Takayasu Kurata

3 joint publications

Eiki Kikuchi

3 joint publications

Makoto Nishio

3 joint publications

Akihiko Gemma